Anodyne Nanotech welcomes Jeff Mihm to its Board of Directors

– USA, MA –  Anodyne Nanotech, Inc., a biotechnology company specializing in the transdermal delivery of biologics, today announced the appointment of Jeff Mihm to its Board of Directors.

“We are thrilled to welcome Jeff Mihm to our Board of Directors. He brings a wealth of experience and expertise in the pharmaceutical industry. We are confident he will be a valuable addition to Anodyne as we advance our Hero Patch platform and develop innovative new products for the delivery of biologics, with a specific focus on peptide therapeutics and monoclonal antibodies,” said CEO, Jake Lombardo.

About Jeff Mihm

Jeff Mihm previously served as the CEO of Noven Pharmaceuticals, a leading transdermal company. During his tenure as CEO, Noven gained FDA approval for a novel transdermal prescription patch product, transformed its manufacturing and quality system,s and implemented a new strategic direction for the company. Mr. Mihm has significant experience with strategic partnerships and licensing transactions, including through Noven’s long-running joint venture with Novartis. Mr. Mihm played an integral role in the $428 million sale of Noven to Hisamitsu Pharmaceuticals. He currently serves as the Executive-in-Residence at the College of Pharmacy and the McCombs School of Business at the University of Texas at Austin.

“I am excited to join Anodyne’s Board of Directors and start working with the management team,” said Mr. Mihm. “I believe Anodyne’s microneedle platform technology has the potential to completely transform the transdermal industry and provide tremendous benefits to future patients.”

About Anodyne Nanotech

Anodyne Nanotech is a Boston-based biotechnology company dedicated to improving human health by developing innovative and efficient methods of delivering biologic drugs. The company is advancing its patented, solid-state porous microneedle technology—the Hero Patch—to deliver clinically-meaningful doses of macro-molecules without the need for injections via traditional hypodermic needles.

For more information: https://www.theheropatch.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.